Round Table Audience Q&A Two | RT Irvine, CA Nov 5, 2022
The HealthTree Foundation for Multiple Myeloma brings information from the experts to the patients! Learn more at https://www.healthtree.org/myeloma/community
Donate to the HealthTree Foundation for Multiple Myeloma or learn more about additional myeloma support we offer here: https://give.healthtree.org/campaign/healthtree-foundation-10-year-celebration/c440295
HealthTree Cure Hub helps you find your best treatment options and accelerate a cure for multiple myeloma. Join today at https://www.healthtree.org/
Follow HealthTree:
twitter.com/healthtreeformm
facebook.com/healthtreeformultiplemyeloma
instragram.com/healthtreeformultiplemyeloma
Видео Round Table Audience Q&A Two | RT Irvine, CA Nov 5, 2022 канала HealthTree Foundation for Multiple Myeloma
Donate to the HealthTree Foundation for Multiple Myeloma or learn more about additional myeloma support we offer here: https://give.healthtree.org/campaign/healthtree-foundation-10-year-celebration/c440295
HealthTree Cure Hub helps you find your best treatment options and accelerate a cure for multiple myeloma. Join today at https://www.healthtree.org/
Follow HealthTree:
twitter.com/healthtreeformm
facebook.com/healthtreeformultiplemyeloma
instragram.com/healthtreeformultiplemyeloma
Видео Round Table Audience Q&A Two | RT Irvine, CA Nov 5, 2022 канала HealthTree Foundation for Multiple Myeloma
Показать
Комментарии отсутствуют
Информация о видео
8 декабря 2022 г. 1:57:13
00:28:23
Другие видео канала
![CELMoDs® Mezigdomide | Paul Richardson, MD | IMS 2022](https://i.ytimg.com/vi/i_hn7jiwJjo/default.jpg)
![The HealthTree Foundation 10 Year Anniversary](https://i.ytimg.com/vi/yFw06QnBIls/default.jpg)
![Medicare 101 for Myeloma Patients: What You Need to Know for 2023](https://i.ytimg.com/vi/f1KQPIOBRo4/default.jpg)
![Mezigdomide, Tazemetostat, and Dex in RRMM: Results from CA057-003 | Luciano Costa, MD | EHA 2024](https://i.ytimg.com/vi/9th9Zueob7U/default.jpg)
![MCRT Baltimore 2018: Immunotherapy for Multiple Myeloma by Ivan Borrello, MD](https://i.ytimg.com/vi/CaFqPRGEe3Y/default.jpg)
![ASH 2019: New Drugs Targeting BCMA — Immunotherapy for Myeloma | Dr. Gareth Morgan](https://i.ytimg.com/vi/mRnjTrFpSeA/default.jpg)
![Exciting Advances in Myeloma Treatment | Timothy Schmidt, MD | ASCO 2023](https://i.ytimg.com/vi/eSyF8IXp77U/default.jpg)
![HealthTree University: Free Myeloma Education for All](https://i.ytimg.com/vi/A6U2ChxjtuM/default.jpg)
![ImmunoPET- an Advanced Companion to MRD Testing](https://i.ytimg.com/vi/1ut5abb27Oo/default.jpg)
![Health Disparities Related to CAR-T Therapy in Myeloma | Samer Al Hadidi, MD | ASH 2021](https://i.ytimg.com/vi/TLaY3cRCXnA/default.jpg)
![First-line Vs. Second-Line Treatment | Matthew LeBlanc, PhD | IMS 2022](https://i.ytimg.com/vi/7PnS63MpePY/default.jpg)
![MASTER Trial Update: MRD based response adaptive therapy | Luciano Costa, MD, PhD | ASH 2021](https://i.ytimg.com/vi/XwuMkv8LqU8/default.jpg)
![Quad Therapies and Side Effects | Nathan Sweeney, PhD | ASH 2022](https://i.ytimg.com/vi/JTqQCn2FHiI/default.jpg)
![Saad Usmani, MD: How Do We Assess Multiple Myeloma Response in 2018? MCRT Charlotte 2018](https://i.ytimg.com/vi/gdlkX5JGEDQ/default.jpg)
![iSTOPMM study and early MGUS and SMM screening | Joshua Richter, MD | ASH 2021](https://i.ytimg.com/vi/mUA_n84ERWI/default.jpg)
![MCRT San Diego 2020: Myeloma Expert Panel – Q&A Afternoon Session](https://i.ytimg.com/vi/WXPE2lEypnY/default.jpg)
![Clinical Trial: INSIGHT Trial by Takeda Oncology](https://i.ytimg.com/vi/mfClvrgbxZk/default.jpg)
![Benjamin Derman, MD | MCRT Chicago, Illinois April 30, 2022](https://i.ytimg.com/vi/quT0Z9miSag/default.jpg)
![Vaccinations & iStopMM Trial | Natalie Callander, MD | IMS 2022](https://i.ytimg.com/vi/ZEawHiMA-jI/default.jpg)
![Taking Your Fitness Routine to the Next Level](https://i.ytimg.com/vi/L1Qbb3eQMtU/default.jpg)